Compare Novartis AG (NVS) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Teladoc Health Inc — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while Teladoc Health Inc trades at $6.83 (market cap $1.29B). The key difference: Novartis AG is far larger — about 231.1× Teladoc Health Inc's market cap, and Novartis AG pays a 3.02% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| NVS | TDOC | |
|---|---|---|
Market Cap | $298.18B | $1.29B |
Sector | Health | Health |
52-Week High | $168.62 | $9.72 |
52-Week Low | $119.31 | $4.47 |
Enterprise Value | $339.50B | $1.55B |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
